{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:50:47Z","timestamp":1767927047862,"version":"3.49.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:p>\n                    This study aims to analyze and identify primary research trends in targeted therapy for thyroid carcinoma (TC). It seeks to provide a factual foundation for researchers, as TC often presents with advanced stages and aggressive subtypes, leading to unfavorable clinical outcomes. The evolution of targeted therapies introduces promising treatment possibilities, necessitating a bibliometric analysis to better understand the current state and trends in this field. A comprehensive bibliometric analysis was conducted using data from the Web of Science Core Collection (WOSCC). Advanced search queries established a literature database, and the analysis was performed using tools such as VOSviewer, CiteSpace, Tableau, and Microsoft Excel. The study focused on publications from 2013 to 2023, examining patterns, geographical contributions, institutional output, and influential journals. The analysis identified 763 publications on TC targeted therapy during the study period, with significant contributions from the United States, China, and Italy, and the United States leading in output. Research activity peaked in 2021, showing overall fluctuating growth. Key contributing institutions included the University of Texas MD Anderson Cancer Center and the University of Pisa. Notable journals, such as\n                    <jats:italic toggle=\"yes\">Cancers<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Thyroid<\/jats:italic>\n                    , were among the most cited, underscoring their impact in the field. The study highlighted an increase in global research output and robust international collaborations, particularly among the leading contributing countries. This bibliometric analysis provides a comprehensive overview of significant contributions and trends in targeted therapy research for TC. It identifies key development processes and research hotspots, offering valuable insights to guide future research directions. The findings aim to stimulate further studies and foster advancements in this critical area of oncology.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000041835","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:02:42Z","timestamp":1742310162000},"page":"e41835","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A visualization analysis of global research trends in targeted therapies for thyroid carcinoma (2013\u20132023)"],"prefix":"10.1097","volume":"104","author":[{"given":"Yu","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-8748","authenticated-orcid":false,"given":"Yi","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-018-0866-1","article-title":"Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.","volume":"17","author":"Pstr\u0105g","year":"2018","journal-title":"Mol Cancer"},{"key":"R2-20260108","first-page":"69","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.3390\/ijms23179872","article-title":"Efficacy of combination therapy with lenvatinib and radioactive iodine in thyroid cancer preclinical model.","volume":"23","author":"Suzuki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"830760","DOI":"10.3389\/fendo.2022.830760","article-title":"Differences between cancer-specific survival of patients with anaplastic and primary squamous cell thyroid carcinoma and factors influencing prognosis: a SEER Database Analysis.","volume":"13","author":"Jin","year":"2022","journal-title":"Front Endocrinol"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/ijms20020454","article-title":"HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer.","volume":"20","author":"Lin","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R6-20260108","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","article-title":"Preclinical development of molecular-targeted agents for cancer.","volume":"8","author":"Ocana","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.15252\/emmm.201505774","article-title":"VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.","volume":"9","author":"Comunanza","year":"2017","journal-title":"EMBO Mol Med"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/annonc\/mdy261","article-title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.","volume":"29","author":"Krug","year":"2018","journal-title":"Ann Oncol"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond.","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","article-title":"Molecular targets of tyrosine kinase inhibitors in thyroid cancer.","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms21010010","article-title":"Multikinase inhibitor treatment in thyroid cancer.","volume":"21","author":"Ancker","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/j.wneu.2024.02.003","article-title":"Hotspot analysis and frontier exploration of stem cell research in intervertebral disc regeneration and repair: a bibliometric and visualization study.","volume":"184","author":"Yang","year":"2024","journal-title":"World Neurosurg"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2147\/JPR.S428991","article-title":"Bibliometric and visualization analysis of biomechanical research on lumbar intervertebral disc.","volume":"16","author":"Hou","year":"2023","journal-title":"J Pain Res"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"1243151","DOI":"10.3389\/fnins.2023.1243151","article-title":"Research hotspots and trends of brain-computer interface technology in stroke: a bibliometric study and visualization analysis.","volume":"17","author":"Li","year":"2023","journal-title":"Front Neurosci"},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"74612","DOI":"10.1007\/s11356-023-27642-6","article-title":"The global scenario of hydrogeochemical research on glacier meltwater: a bibliometric and visualization analysis.","volume":"30","author":"Kumar","year":"2023","journal-title":"Environ Sci Pollut Res Int"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"issue":"Suppl 1","key":"R18-20260108","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization.","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R19-20260108","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases.","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"e34002","DOI":"10.1097\/MD.0000000000034002","article-title":"Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: a bibliometric study.","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2147\/JPR.S450586","article-title":"Bibliometric and visualization analysis of research hotspots and frontiers in endoscopic lumbar discectomy.","volume":"17","author":"Zhong","year":"2024","journal-title":"J Pain Res"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"969196","DOI":"10.3389\/fimmu.2022.969196","article-title":"A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer.","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1530\/eje.1.02158","article-title":"European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.","volume":"154","author":"Pacini","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer.","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer.","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors.","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"R36-20260108","first-page":"1184","article-title":"Dabrafenib Versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, Phase 2, Open-Label Multicenter Trial.","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma.","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/thy.2018.0424","article-title":"Lysyl Oxidase Is a Key Player in BRAF\/mapk pathway-driven thyroid cancer aggressiveness.","volume":"29","author":"Boufraqech","year":"2019","journal-title":"Thyroid"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ctrv.2015.06.005","article-title":"PI3K\/Akt\/mTOR: a promising therapeutic target for non-medullary thyroid carcinoma.","volume":"41","author":"Petrulea","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-12-0405","article-title":"Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.","volume":"167","author":"Schneider","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.","volume":"27","author":"de Groot","year":"2006","journal-title":"Endocr Rev"},{"key":"R43-20260108","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.3390\/cancers14184442","article-title":"Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer.","volume":"14","author":"Saronni","year":"2022","journal-title":"Cancers"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41392-020-00231-6","article-title":"CYP2S1 is a synthetic lethal target in BRAFV600E-driven thyroid cancers.","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-13-45","article-title":"MEK targeting in N-RAS mutated metastatic melanoma.","volume":"13","author":"Thumar","year":"2014","journal-title":"Mol Cancer"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.7150\/thno.19884","article-title":"c-Myc is Required for BRAFV600E-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis.","volume":"7","author":"Qu","year":"2017","journal-title":"Theranostics"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.3390\/ijms23105684","article-title":"SK119, a novel shikonin derivative, leads to apoptosis in melanoma cell lines and exhibits synergistic effects with vemurafenib and cobimetinib.","volume":"23","author":"Kretschmer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R49-20260108","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acs.jproteome.9b00134","article-title":"Quantitative interrogation of the human kinome perturbed by two BRAF Inhibitors.","volume":"18","author":"Miao","year":"2019","journal-title":"J Proteome Res"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib Redifferentiation of BRAF Mutant, RAI-refractory thyroid cancers.","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"R52-20260108","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/nsr\/nwy021","article-title":"On the low reproducibility of cancer studies.","volume":"5","author":"Wen","year":"2018","journal-title":"Natl Sci Rev"},{"key":"R53-20260108","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1038\/509S69a","article-title":"Biology: Three known unknowns.","volume":"509","author":"Bourzac","year":"2014","journal-title":"Nature"},{"key":"R54-20260108","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/01.sla.0000250451.59685.67","article-title":"Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone.","volume":"245","author":"Roh","year":"2007","journal-title":"Ann Surg"},{"key":"R55-20260108","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2012.0043","article-title":"The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.","volume":"22","author":"Randolph","year":"2012","journal-title":"Thyroid"},{"key":"R56-20260108","first-page":"2041","article-title":"Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades.","volume":"80","author":"Dinneen","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R57-20260108","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2967\/jnumed.121.261898","article-title":"Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.","volume":"62","author":"Seifert","year":"2021","journal-title":"J Nucl Med"},{"key":"R58-20260108","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","article-title":"Epithelial-mesenchymal plasticity in cancer progression and metastasis.","volume":"49","author":"Lu","year":"2019","journal-title":"Dev Cell"},{"key":"R59-20260108","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1878-0261.12017","article-title":"Epithelial-mesenchymal transition in tumor metastasis.","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol Oncol"},{"key":"R60-20260108","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-11-1080","article-title":"Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R61-20260108","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"R62-20260108","doi-asserted-by":"crossref","first-page":"1176731","DOI":"10.3389\/fendo.2023.1176731","article-title":"Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.","volume":"14","author":"Hamidi","year":"2023","journal-title":"Front Endocrinol"},{"key":"R63-20260108","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R64-20260108","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study.","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"R65-20260108","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials.","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"R66-20260108","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"R67-20260108","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-Infiltrating T Cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer.","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-20260108","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2016-3756","article-title":"Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study.","volume":"102","author":"Chintakuntlawar","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R69-20260108","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma.","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:00:29Z","timestamp":1767906029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041835","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}